AMAG Pharmaceuticals Appoints Tony Casciano as Senior Vice President of Hematology/Oncology Sales and Marketing

WALTHAM, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today the appointment of Tony Casciano to senior vice president of sales and marketing for the company’s Hematology and Oncology business.  He will report to Nik Grund, AMAG’s chief commercial officer.

“Tony Casciano has a proven track record of building profitable businesses and launching new products,” said Mr. Grund. “This experience will be an asset to expanding AMAG’s Hematology and Oncology unit and increasing market share both with existing products and new business development opportunities.”

Mr. Casciano brings to AMAG more than 15 years of sales and marketing experience and began his career at Sanofi US in 2000. He has advanced through commercial positions of increasing responsibility across a broad range of therapeutic areas, and most recently served as the head of marketing for Sanofi where he led the General Medicine division.

Mr. Casciano holds a Bachelor of Science degree in business administration from Bridgewater State College.

Inducement Equity Awards

In connection with Mr. Casciano’s entering into employment with AMAG, the Board of Directors of AMAG approved awards to Mr. Casciano of (i) an option to purchase 20,000 shares of common stock and (ii) 10,000 restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option will have a ten-year term and be subject to the terms and conditions of the stock option agreement pursuant to which the option will be granted. The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted. These equity awards will be granted without stockholder approval as inducements material to Mr. Casciano entering into employment with AMAG in accordance with NASDAQ Listing Rule 5635(c)(4).

About AMAG

AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit

Forward Looking Statements  

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding Mr. Casciano’s contributions and responsibilities, including AMAG’s belief that Mr. Casciano’s experience will be an asset to expanding AMAG’s Hematology and Oncology unit and increasing market share both with existing products and new business development opportunities are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include, among others, those identified in AMAG’s Securities and Exchange Commission (SEC) filings, including AMAG’s Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2016 and June 30, 2016 and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.  CBR® is a registered trademark of CBR Systems, Inc.

AMAG Pharmaceuticals, Inc. Contact:

Maryann Cimino
Manager, Corporate Communications & External Affairs

Primary Logo

AMAG Pharmaceuticals, Inc.